Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
Integra LifeSciences (IART) reported preliminary Q3 2026 results, with revenue of $410M-$412M and adjusted EPS of $0.55-$0.59. The company lowered full-year 2026 guidance due to flooding at its Cincinnati facility, expecting revenue of $1.634B-$1.654B and adjusted EPS of $2.30-$2.40. The facility disruption is estimated to impact Q3 revenue by $7M and Q4 revenue by $15M-$20M. The company expects insurance to mitigate earnings impact.
How this was made
The 30-second read
Why it matters
The guidance downgrade reflects operational disruption and may trigger short‑term sell‑offs, but insurance recoveries and cash flow expectations could mitigate longer‑term concerns.
Market read
First‑hand guidance update for a mid‑cap healthcare company; likely influences its stock and peers in the medical‑technology sector.
What to watch
Potential insurance recoveries could offset some of the earnings hit, and the company expects strong cash generation.
Background
Integra LifeSciences disclosed that July flooding at its Cincinnati facility impaired production, prompting a $7 million Q3 revenue hit and a $15‑$20 million Q4 hit, leading to a modest guidance reduction.
Ticker impact
Integra LifeSciences released unaudited preliminary Q3 2026 results and lowered full‑year 2026 revenue and EPS guidance.
likely downward pressure as investors price in lower revenue and EPS outlook
The company reduced its full‑year revenue range by $20‑$30 million and EPS guidance by $0.10, a material downgrade for a mid‑cap medical‑technology firm.
Market effects
May weigh on other medical‑technology stocks as investors reassess flood‑risk exposures.
Limited to U.S. and North‑American healthcare equities.
Low global impact; primarily a company‑specific earnings update.
Counterpoint
If the flood impact is over‑estimated, the guidance cut could be premature, offering a buying opportunity on a dip.
Key entities
- CompanyIntegra LifeSciences Holdings Corp.
Medical‑technology firm reporting preliminary Q3 results and revised 2026 guidance.
- ExecutiveStuart Essig
Chairman and CEO of Integra LifeSciences, provided commentary on the flood impact.
